新辅助化疗后组织病理变化对乳腺癌患者存活率的影响
Sabine Danzinger1, Verena Heiss Spornberger1, Hannes Vietzen2
1Department of Obstetrics and Gynecology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Cancer treatment and research communications
|March 3, 2025
概括
新辅助化疗后乳腺癌生物标志物的变化显著影响患者的预后. 监测雌激素受体,孕激素受体,Ki67和亚型转变对于预测早期乳腺癌的结果至关重要.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
- 医学研究 医学研究
背景情况:
- 新辅助化疗 (NACT) 是早期乳腺癌 (BC) 的标准治疗方法.
- 在NACT之前和之后的组织病理学分析对于了解治疗反应至关重要.
- 在NACT后评估BC生物标志物的变化可以揭示预后信息.
研究的目的:
- 分析NACT后早期乳腺癌患者的组织病理参数变化.
- 确定这些NACT后生物标志物变化的预后影响.
- 为了将生物标志物转换与无病生存率 (DFS) 和整体生存率 (OS) 相关联.
主要方法:
- 早期BC患者接受NACT治疗后进行手术的回顾性分析.
- 排除了获得病理完整反应 (pCR) 的患者.
- 对瘤等级,ER,PR,HER2,Ki67和BC亚型转换的评估.
- 在平均随访时间为58.03个月后,对DFS和OS的生存分析.
主要成果:
- 对瘤等级 (34.6%) 和Ki67 (30.0%) 观察到显著的转化率.
- 持续负的ER/PR与最差的预后相关 (DFS和OS).
- 从高基67转换为低基67改善了结果;NACT后的非三阴性 (nTN) 亚型显示出比三阴性 (TN) 亚型更好的预后.
结论:
- 瘤等级和Ki67在NACT后表现出最高的转化率.
- 在NACT后ER,PR,Ki67和BC亚型的变化显著影响患者的预后.
- 后NACT生物标志物状态是早期BCDFS和OS的关键决定因素.
更多相关视频
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.2K
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
8.8K
相关概念视频
01:21Cancer Survival Analysis
319
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
319
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K